Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19

MeSH terms

• Antiviral Agents / therapeutic use
• Apyrase / antagonists & inhibitors
• Apyrase / genetics
• Apyrase / immunology
• B-Lymphocytes / immunology
• B-Lymphocytes / pathology
• B7-H1 Antigen / antagonists & inhibitors
• B7-H1 Antigen / genetics
• B7-H1 Antigen / immunology
• Betacoronavirus / immunology
• Betacoronavirus / pathogenicity*
• COVID-19
• Case-Control Studies
• Coronavirus Infections / drug therapy
• Coronavirus Infections / genetics
• Coronavirus Infections / immunology*
• Coronavirus Infections / virology
• Gene Expression / drug effects
• Humans
• Immunologic Factors / therapeutic use
• Killer Cells, Natural / drug effects
• Killer Cells, Natural / immunology
• Killer Cells, Natural / pathology
• Molecular Targeted Therapy / methods*
• NK Cell Lectin-Like Receptor Subfamily C / antagonists & inhibitors
• NK Cell Lectin-Like Receptor Subfamily C / genetics
• NK Cell Lectin-Like Receptor Subfamily C / immunology
• Pandemics
• Pneumonia / drug therapy
• Pneumonia / genetics
• Pneumonia / immunology*
• Pneumonia / virology
• Pneumonia, Viral / drug therapy
• Pneumonia, Viral / genetics
• Pneumonia, Viral / immunology*
• Pneumonia, Viral / virology
• Programmed Cell Death 1 Receptor / antagonists & inhibitors
• Programmed Cell Death 1 Receptor / genetics
• Programmed Cell Death 1 Receptor / immunology
• SARS-CoV-2
• Severe Acute Respiratory Syndrome / drug therapy
• Severe Acute Respiratory Syndrome / genetics
• Severe Acute Respiratory Syndrome / immunology*
• Severe Acute Respiratory Syndrome / virology
• T-Lymphocyte Subsets / immunology
• T-Lymphocyte Subsets / pathology